Program
andexanet alfa
Also written as “Andexanet”, “Andexanet alfa” and “Andexanet alfa (infusion IV)”.
Its studies are mostly in Hemorrhage · Thrombosis, led by AstraZeneca.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 140 open or running | phase 4since Aug 30, 2018 | Dec 18, 2012 | none ahead |
Also a collaborator on its studies: Parexel and Portola Pharmaceuticals, LLC (a wholly owned subsidiary of Alexion Pharmaceuticals).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 18, 2012First study: phase 2 study in Healthy VolunteersFirst studyNCT01758432 · 54 enrolled · United States
- Dec 27, 2012Phase 1 study in HealthyNCT03218241 · 32 enrolled · United States
- Apr 28, 2014Phase 3 study in HemorrhageNCT02207725 · 68 enrolled · United States
- Aug 18, 2014Phase 3 study in HemorrhageNCT02220725 · 80 enrolled · United States
- Dec 18, 2014Phase 3 study in HemorrhageNCT02329327 · 479 enrolled · United States, Belgium, Canada and more
- Mar 7, 2017Phase 1 study in HemorrhageNCT03083704 · 153 enrolled · United States
- Sep 27, 2017Phase 2 study in HemorrhageNCT03330457 · 18 enrolled · United States
- May 15, 20183 phase 2 studies in Healthy VolunteersNCT03578146, NCT03551743, NCT03551730
- Aug 30, 2018Phase 4 study in ThrombosisNCT03661528 · 530 enrolled · United States, Austria, Belgium and more
- Jan 14, 2020Phase 2 study in ThrombosisNCT04233073 · 10 enrolled · United States, Austria, France and more
- Jun 9, 2023Phase 3 study in Urgent SurgeryNCT05926349
- Nov 27, 2025Phase 1 study in Healthy ParticipantsNCT07312851 · 191 enrolled · Germany, United Kingdom
TargetBeta
“Rivaroxaban sequestering agent; Apixaban sequestering agent; Tissue factor pathway inhibitor inhibitor”ChEMBL 37, by rule
Other programs on TFPI
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| marstacimabrule | Pfizer | phase 3 | 10 |
Studies
All 14 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07312851Healthy Participants · Germany, United Kingdom | 1 | Completed | Jun 22, 2026 | 191 |
| NCT05926349Urgent Surgery | 3 | Withdrawn | Jan 5, 2027 | 0 |
| NCT04233073Thrombosis · United States, Austria, France and more | 2 | Terminated | Nov 23, 2021 | 10 |
| NCT03661528Thrombosis · United States, Austria, Belgium and more | 4 | Completed | May 27, 2023 | 530 |
| NCT03578146Healthy Volunteers | 2 | Completed | Sep 2015 | 48 |
| NCT03551743Healthy Volunteers | 2 | Completed | Sep 2015 | 28 |
| NCT03551730Healthy Volunteers · United States | 2 | Completed | Sep 2015 | 27 |
| NCT03330457Hemorrhage · United States | 2 | Terminated | Feb 22, 2016 | 18 |
| NCT03083704Hemorrhage · United States | 1 | Completed | Sep 28, 2017 | 153 |
| NCT02329327Hemorrhage · United States, Belgium, Canada and more | 3 | Completed | Sep 24, 2020 | 479 |
| NCT02220725Hemorrhage · United States | 3 | Completed | Aug 2015 | 80 |
| NCT02207725Hemorrhage · United States | 3 | Completed | Apr 2015 | 68 |
| NCT03218241Healthy · United States | 1 | Completed | Sep 2012 | 32 |
| NCT01758432Healthy Volunteers · United States | 2 | Completed | Sep 2015 | 54 |
How it is read
Names in the registry
- “Andexanet”, 3 entries
- “Andexanet alfa”, 2 entries
- “andexanet alfa”, 2 entries
- “Andexanet alfa (infusion IV)”, 1 entry
- “Andexanet alfa (Gen 1 Process 2)”, 1 entry
Conditions, from the studies’ own filings
- Hemorrhage, 5 studies
- Thrombosis, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.